This suggests that the impact of VHL mutations is more pronounced in earlier stages when assessing the potential for metastatic disease.76 This highlights the complexity and adaptability of RCC tumors in evading immune surveillance, especially considering the near-universal presence of alterations in hypoxia sensing mechanisms, such as VHL mutations, in these tumors. This evidence concerns the gene VHL and metastatic neoplasm.